Evergreen — last updated June 2026

The state of the field

For thirty years, the category had two drugs and a scalpel. The research map is now wider than it has ever been. Here's how to read it without getting played.

By the Editorial Team · Citations below · Medical review: pending — treat as education, not advice

The settled ground

Approved and well-evidenced for male androgenetic alopecia: oral finasteride, topical minoxidil, and hair transplantation. Each has its own briefing in this Journal. Low-dose oral minoxidil and topical finasteride are growing off-label and formulation-research areas riding on the same two mechanisms.

Research direction 1: the follicle as a stem-cell problem

Pattern hair loss doesn't kill follicles outright — it miniaturizes them, and the stem-cell populations that drive the growth cycle persist but go quiescent. A significant slice of current research asks how to reactivate those resident progenitor cells or restore the signaling environment (Wnt/β-catenin and related pathways) that tells them to cycle. This is the conceptual shift of the decade: from slowing loss hormonally to restarting growth biologically. The most-watched clinical example of this approach is covered in our dedicated briefing on PP405.

Research direction 2: beyond the DHT axis

Finasteride's success made DHT the category's center of gravity, but newer programs explore targets outside it — topical androgen-receptor approaches designed to act in skin without systemic hormonal effects, prostaglandin-pathway modulation, and metabolic levers affecting the follicle's energy supply. The shared goal: efficacy without the systemic side-effect conversation that shadows oral antiandrogens.

Research direction 3: lessons from alopecia areata

A note of earned optimism from a neighboring condition: alopecia areata — an autoimmune disease, biologically distinct from pattern loss — got its first FDA-approved systemic treatments in 2022–2023 (JAK inhibitors baricitinib and ritlecitinib). That matters here for one reason: it proved the regulatory and commercial path for serious hair-biology drugs, ending the era when hair was dismissed as a cosmetic backwater. It does not mean JAK inhibitors treat pattern baldness — they don't, and the conditions shouldn't be conflated.

Research direction 4: regeneration and cell therapy

The furthest horizon: follicle neogenesis — culturing or engineering follicle-forming cell populations and returning them to the scalp — along with exosome and platelet-derived approaches of widely varying rigor. PRP (platelet-rich plasma) already has a clinical literature with mixed, protocol-dependent results; cultured-cell approaches remain largely preclinical or early-stage. This is the zone with the largest gap between conference-room excitement and published human data, and therefore the zone where consumer skepticism earns the highest return.

How to read pipeline news

1. Find the phase. Preclinical, Phase 1 (safety), Phase 2 (signal), Phase 3 (proof). Most coverage buries this.
2. Find the endpoint. "Increased hair count" vs. photographic assessment vs. patient-reported — they are not interchangeable.
3. Find the n. Twenty-person open-label studies generate headlines; they don't generate knowledge.
4. Watch for the conditional. "Could," "may," "potentially" — the load-bearing words in every breathless pipeline story.
5. Remember attrition. Most investigational drugs in every field fail between Phase 2 and approval. Pricing hope accordingly isn't cynicism; it's arithmetic.

This page is updated as the literature moves. Waitlist members get the change-log in their briefings.